Windtree Therapeutics to Host Virtual R&D and Investor Day Focusing on the Cardiogenic Shock Market, Istaroxime, Company Strategy and Planned Near-Term Milestones
June 05, 2023 08:00 ET
|
Windtree Therapeutics
Virtual event to take place on June 14, 2023 at 1:00 pm ET WARRINGTON, Pa., June 05, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a...
Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates
May 15, 2023 16:30 ET
|
Windtree Therapeutics
WARRINGTON, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
Windtree Therapeutics Announces Publication from Its SEISMiC Pre Cardiogenic Shock Study Comparing Two Doses of Istaroxime
April 27, 2023 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT) is a biotechnology company focused on advancing late-stage...
Windtree Therapeutics Announces Closing of $12.42 Million Underwritten Public Offering Including Full Exercise of Overallotment Option
April 24, 2023 16:01 ET
|
Windtree Therapeutics
WARRINGTON, Pa., April 24, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
Windtree Therapeutics Announces Pricing of Upsized $10.8 Million Underwritten Public Offering
April 20, 2023 08:30 ET
|
Windtree Therapeutics
WARRINGTON, Pa., April 20, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
Windtree Therapeutics Announces Issuance of New Dual Mechanism SERCA2a Activator Patent
April 17, 2023 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., April 17, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
Windtree Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Key Business Updates
April 03, 2023 07:35 ET
|
Windtree Therapeutics
WARRINGTON, Pa., April 03, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular...
Windtree Regains Compliance with Nasdaq
March 13, 2023 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., March 13, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
Windtree Finds Cardiogenic Shock Has High Cost of US Patient Care and Plans Innovation with the Unique Profile of Istaroxime
March 06, 2023 08:00 ET
|
Windtree Therapeutics
US Hospital Claims Data Reveals Cardiogenic Shock Patients Have an Average Hospital Length of Stay of 19.6 Days Making Its Intensive Patient Care Cost Very High WARRINGTON, Pa., March 06, 2023 ...
Windtree Announces Publication on its SERCA2a Activator Drug Candidate for Chronic and Acute Heart Failure
February 28, 2023 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage...